

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY)
NEW DRUG APPLICATION ACCEPTED FOR REVIEW BY NMPA

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that the Center for Drug Evaluation (the “**CDE**”) of the National Medical Products Administration of the People’s Republic of China (the “**NMPA**”) has accepted the New Drug Application (the “**NDA**”) for the Company’s self-developed drug candidate LBL-024 (Opamtistomig, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of previously treated advanced extrapulmonary neuroendocrine carcinoma (“**EP-NEC**”). LBL-024 is the first PD-L1/4-1BB bispecific antibody worldwide for which a marketing application has been submitted, and such application was granted priority review by the CDE on July 10, 2026. If approved, LBL-024 would become the first approved antibody worldwide directly targeting 4-1BB, as well as the first approved agonistic antibody. Its approval would also make 4-1BB the fourth immuno-oncology target worldwide with an approved therapy, following PD-1/PD-L1, CTLA-4 and LAG-3, representing a significant milestone for China’s innovative drug industry in the field of cancer immunotherapy.

The NDA is supported by positive results from a pivotal registrational clinical study led by Professor Shen Lin (沈琳) of Peking University Cancer Hospital (北京大學腫瘤醫院), with participation from 34 hospitals. Enrollment of all 96 patients with EP-NEC was completed in August 2025. Detailed clinical study results are planned to be presented at a leading international scientific conference.

ABOUT EP-NEC

Neuroendocrine carcinoma (“**NEC**”) is a highly malignant immunologically “cold” tumor, accounting for approximately 10% to 20% of neuroendocrine neoplasms. NEC may arise in various organs, including the lung, gastrointestinal tract and bladder. NEC can be classified into pulmonary NEC and extrapulmonary NEC. EP-NEC shares the highly aggressive and metastatic characteristics of small cell lung cancer (“**SCLC**”), progresses rapidly, and most patients with NEC present with advanced-stage disease or distant metastases at diagnosis. Systemic treatment options for NEC are limited, with suboptimal efficacy and poor prognosis.

There are currently no therapies specifically approved by regulatory authorities worldwide for EP-NEC. First-line treatment for advanced EP-NEC primarily consists of platinum-based chemotherapy, with an objective response rate (“**ORR**”) of approximately 30% to 50% and a median overall survival (“**mOS**”) of only around one year. There is no standard treatment following progression on first-line therapy. Second-line treatment options may include oxaliplatin-based FOLFOX, irinotecan-based FOLFIRI, CAPTEM with or without bevacizumab, or temozolomide monotherapy. However, the efficacy of these treatment options remains limited, with an ORR of approximately 10% to 25% and an mOS of approximately eight months. Accordingly, there remains a substantial unmet medical need for patients with advanced EP-NEC, underscoring the urgent need for new and effective treatment options.

ABOUT LBL-024 (OPAMTISTOMIG)

LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB, and is a pan-tumor IO 2.0 cornerstone therapy with potential survival benefit. Leveraging our self-developed X-body™ platform with full intellectual property rights, LBL-024 achieves conditional activation of 4-1BB, relieving PD-1/PD-L1 immunosuppression while enhancing 4-1BB regulated T-cell activation, achieving a synergistic effect in eliminating tumors. LBL-024 demonstrates a safety profile comparable to PD-1/PD-L1 inhibitors and greater potential for broad-spectrum cancer treatment, and has demonstrated first-in-class (FIC) or best-in-class (BIC) potential in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (EP-NEC) and biliary tract cancer (BTC), among other tumor types.

As the first molecule targeting the co-stimulatory receptor 4-1BB to have reached the pivotal single-arm registrational clinical stage globally, LBL-024 has the potential to become the first drug approved for treating EP-NEC. LBL-024 has initiated clinical studies across 13 solid tumor indications in China, including one pivotal registrational clinical study and eight proof-of-concept studies, covering EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC) and melanoma, among other areas with high unmet medical needs.

In particular, activation of the 4-1BB co-stimulatory pathway may restore and enhance the activity of exhausted T cells and promote their proliferation, making 4-1BB-targeted therapies potentially suitable for the treatment of immunologically “cold tumors” that are resistant or unresponsive to PD-1/PD-L1 inhibitors, and potentially capable of conferring durable survival benefits with a long-tail effect. In October 2024, LBL-024 was granted Breakthrough Therapy Designation by the Center for Drug Evaluation of the NMPA, and in November 2024, it received Orphan Drug Designation from the U.S. Food and Drug Administration (the “FDA”). In January 2026, LBL-024 was granted Fast Track Designation by the FDA and Orphan Drug Designation in the European Union.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-024, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, August 21, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.